These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3772915)

  • 1. Clinical experience with multiphasic oral contraceptives.
    Policar M
    J Reprod Med; 1986 Sep; 31(9 Suppl):939-45. PubMed ID: 3772915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pill formulations and their effect on lipid and carbohydrate metabolism.
    Brooks PG
    J Reprod Med; 1984 Jul; 29(7 Suppl):539-46. PubMed ID: 6481707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiphasic oral contraceptives. Efficacy and metabolic impact.
    Ellis JW
    J Reprod Med; 1987 Jan; 32(1):28-36. PubMed ID: 3550064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for a triphasic oral contraceptive.
    Pasquale SA
    J Reprod Med; 1984 Jul; 29(7 Suppl):560-7. PubMed ID: 6481710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptives.
    Shearman RP
    Aust Fam Physician; 1984 Sep; 13(9):685-91. PubMed ID: 6508652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OC practice guidelines: minimizing side effects.
    Darney PD
    Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives and metabolic risk markers for coronary heart disease.
    Crook D; Godsland IF; Wynn V
    Int J Fertil; 1991; 36 Suppl 1():38-46. PubMed ID: 1678380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspectives on combination oral contraceptives.
    Smith MA; Youngkin EQ
    Clin Pharm; 1984; 3(5):485-96. PubMed ID: 6386284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral contraceptives and metabolic changes].
    Lara Ricalde R; Aznar Ramos R
    Ginecol Obstet Mex; 1986 Aug; 54():212-5. PubMed ID: 3781292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral contraception: failures and risks].
    Foussard-blanpin O; Paillot-renaud P; Bruneau-bigot A
    Lyon Pharm; 1984 Nov; 35(6):385-93. PubMed ID: 12280590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metabolic risks of oral contraception].
    Monier L
    Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and the risk of cardiovascular disease.
    Med Lett Drugs Ther; 1983 Jul; 25(640):69-70. PubMed ID: 6865850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in oral contraception. An international review of levonorgestrel and ethinyl estradiol.
    Goldzieher JW
    J Reprod Med; 1983 Jan; 28(1 Suppl):53-6. PubMed ID: 6403700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.